FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS
The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhanci...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
V. Т. Kokhnyuk [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Тазовая хирургия и онкология - “ABV-press” Publishing house”, LLC, 2021, (2015), 4, Seite 7-11 |
|---|---|
| Übergeordnetes Werk: |
year:2015 ; number:4 ; pages:7-11 |
| Links: |
|---|
| DOI / URN: |
10.17650/2220-3478-2013-0-4-7-11 |
|---|
| Katalog-ID: |
DOAJ08430104X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ08430104X | ||
| 003 | DE-627 | ||
| 005 | 20230503013056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230311s2015 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.17650/2220-3478-2013-0-4-7-11 |2 doi | |
| 035 | |a (DE-627)DOAJ08430104X | ||
| 035 | |a (DE-599)DOAJe91c09e314a647eaa036ee462346ba84 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a V. Т. Kokhnyuk |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009). | ||
| 650 | 4 | |a colorectal cancer | |
| 650 | 4 | |a cancer-specific survival | |
| 650 | 4 | |a adjuvant chemotherapy | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 773 | 0 | 8 | |i In |t Тазовая хирургия и онкология |d “ABV-press” Publishing house”, LLC, 2021 |g (2015), 4, Seite 7-11 |w (DE-627)176063123X |x 26869594 |7 nnns |
| 773 | 1 | 8 | |g year:2015 |g number:4 |g pages:7-11 |
| 856 | 4 | 0 | |u https://doi.org/10.17650/2220-3478-2013-0-4-7-11 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/e91c09e314a647eaa036ee462346ba84 |z kostenfrei |
| 856 | 4 | 0 | |u https://ok.abvpress.ru/jour/article/view/89 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2686-9594 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2015 |e 4 |h 7-11 | ||
| author_variant |
v т k vтk |
|---|---|
| matchkey_str |
article:26869594:2015----::ieeracrpcfcuvvlftgiiooet |
| hierarchy_sort_str |
2015 |
| callnumber-subject-code |
RC |
| publishDate |
2015 |
| allfields |
10.17650/2220-3478-2013-0-4-7-11 doi (DE-627)DOAJ08430104X (DE-599)DOAJe91c09e314a647eaa036ee462346ba84 DE-627 ger DE-627 rakwb rus RC254-282 V. Т. Kokhnyuk verfasserin aut FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009). colorectal cancer cancer-specific survival adjuvant chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 (2015), 4, Seite 7-11 (DE-627)176063123X 26869594 nnns year:2015 number:4 pages:7-11 https://doi.org/10.17650/2220-3478-2013-0-4-7-11 kostenfrei https://doaj.org/article/e91c09e314a647eaa036ee462346ba84 kostenfrei https://ok.abvpress.ru/jour/article/view/89 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2015 4 7-11 |
| spelling |
10.17650/2220-3478-2013-0-4-7-11 doi (DE-627)DOAJ08430104X (DE-599)DOAJe91c09e314a647eaa036ee462346ba84 DE-627 ger DE-627 rakwb rus RC254-282 V. Т. Kokhnyuk verfasserin aut FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009). colorectal cancer cancer-specific survival adjuvant chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 (2015), 4, Seite 7-11 (DE-627)176063123X 26869594 nnns year:2015 number:4 pages:7-11 https://doi.org/10.17650/2220-3478-2013-0-4-7-11 kostenfrei https://doaj.org/article/e91c09e314a647eaa036ee462346ba84 kostenfrei https://ok.abvpress.ru/jour/article/view/89 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2015 4 7-11 |
| allfields_unstemmed |
10.17650/2220-3478-2013-0-4-7-11 doi (DE-627)DOAJ08430104X (DE-599)DOAJe91c09e314a647eaa036ee462346ba84 DE-627 ger DE-627 rakwb rus RC254-282 V. Т. Kokhnyuk verfasserin aut FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009). colorectal cancer cancer-specific survival adjuvant chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 (2015), 4, Seite 7-11 (DE-627)176063123X 26869594 nnns year:2015 number:4 pages:7-11 https://doi.org/10.17650/2220-3478-2013-0-4-7-11 kostenfrei https://doaj.org/article/e91c09e314a647eaa036ee462346ba84 kostenfrei https://ok.abvpress.ru/jour/article/view/89 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2015 4 7-11 |
| allfieldsGer |
10.17650/2220-3478-2013-0-4-7-11 doi (DE-627)DOAJ08430104X (DE-599)DOAJe91c09e314a647eaa036ee462346ba84 DE-627 ger DE-627 rakwb rus RC254-282 V. Т. Kokhnyuk verfasserin aut FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009). colorectal cancer cancer-specific survival adjuvant chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 (2015), 4, Seite 7-11 (DE-627)176063123X 26869594 nnns year:2015 number:4 pages:7-11 https://doi.org/10.17650/2220-3478-2013-0-4-7-11 kostenfrei https://doaj.org/article/e91c09e314a647eaa036ee462346ba84 kostenfrei https://ok.abvpress.ru/jour/article/view/89 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2015 4 7-11 |
| allfieldsSound |
10.17650/2220-3478-2013-0-4-7-11 doi (DE-627)DOAJ08430104X (DE-599)DOAJe91c09e314a647eaa036ee462346ba84 DE-627 ger DE-627 rakwb rus RC254-282 V. Т. Kokhnyuk verfasserin aut FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009). colorectal cancer cancer-specific survival adjuvant chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens In Тазовая хирургия и онкология “ABV-press” Publishing house”, LLC, 2021 (2015), 4, Seite 7-11 (DE-627)176063123X 26869594 nnns year:2015 number:4 pages:7-11 https://doi.org/10.17650/2220-3478-2013-0-4-7-11 kostenfrei https://doaj.org/article/e91c09e314a647eaa036ee462346ba84 kostenfrei https://ok.abvpress.ru/jour/article/view/89 kostenfrei https://doaj.org/toc/2686-9594 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 2015 4 7-11 |
| language |
Russian |
| source |
In Тазовая хирургия и онкология (2015), 4, Seite 7-11 year:2015 number:4 pages:7-11 |
| sourceStr |
In Тазовая хирургия и онкология (2015), 4, Seite 7-11 year:2015 number:4 pages:7-11 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
colorectal cancer cancer-specific survival adjuvant chemotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| isfreeaccess_bool |
true |
| container_title |
Тазовая хирургия и онкология |
| authorswithroles_txt_mv |
V. Т. Kokhnyuk @@aut@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
176063123X |
| id |
DOAJ08430104X |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ08430104X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503013056.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2015 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/2220-3478-2013-0-4-7-11</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ08430104X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe91c09e314a647eaa036ee462346ba84</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V. Т. Kokhnyuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009).</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer-specific survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adjuvant chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Тазовая хирургия и онкология</subfield><subfield code="d">“ABV-press” Publishing house”, LLC, 2021</subfield><subfield code="g">(2015), 4, Seite 7-11</subfield><subfield code="w">(DE-627)176063123X</subfield><subfield code="x">26869594</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2015</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:7-11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/2220-3478-2013-0-4-7-11</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e91c09e314a647eaa036ee462346ba84</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ok.abvpress.ru/jour/article/view/89</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2686-9594</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2015</subfield><subfield code="e">4</subfield><subfield code="h">7-11</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
V. Т. Kokhnyuk |
| spellingShingle |
V. Т. Kokhnyuk misc RC254-282 misc colorectal cancer misc cancer-specific survival misc adjuvant chemotherapy misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS |
| authorStr |
V. Т. Kokhnyuk |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)176063123X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC254-282 |
| illustrated |
Not Illustrated |
| issn |
26869594 |
| topic_title |
RC254-282 FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS colorectal cancer cancer-specific survival adjuvant chemotherapy |
| topic |
misc RC254-282 misc colorectal cancer misc cancer-specific survival misc adjuvant chemotherapy misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_unstemmed |
misc RC254-282 misc colorectal cancer misc cancer-specific survival misc adjuvant chemotherapy misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_browse |
misc RC254-282 misc colorectal cancer misc cancer-specific survival misc adjuvant chemotherapy misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Тазовая хирургия и онкология |
| hierarchy_parent_id |
176063123X |
| hierarchy_top_title |
Тазовая хирургия и онкология |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)176063123X |
| title |
FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS |
| ctrlnum |
(DE-627)DOAJ08430104X (DE-599)DOAJe91c09e314a647eaa036ee462346ba84 |
| title_full |
FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS |
| author_sort |
V. Т. Kokhnyuk |
| journal |
Тазовая хирургия и онкология |
| journalStr |
Тазовая хирургия и онкология |
| callnumber-first-code |
R |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
txt |
| container_start_page |
7 |
| author_browse |
V. Т. Kokhnyuk |
| class |
RC254-282 |
| format_se |
Elektronische Aufsätze |
| author-letter |
V. Т. Kokhnyuk |
| doi_str_mv |
10.17650/2220-3478-2013-0-4-7-11 |
| title_sort |
five-year cancer-specific survival of stage iii colorectal cancer patients |
| callnumber |
RC254-282 |
| title_auth |
FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS |
| abstract |
The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009). |
| abstractGer |
The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009). |
| abstract_unstemmed |
The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009). |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
4 |
| title_short |
FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS |
| url |
https://doi.org/10.17650/2220-3478-2013-0-4-7-11 https://doaj.org/article/e91c09e314a647eaa036ee462346ba84 https://ok.abvpress.ru/jour/article/view/89 https://doaj.org/toc/2686-9594 |
| remote_bool |
true |
| ppnlink |
176063123X |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.17650/2220-3478-2013-0-4-7-11 |
| callnumber-a |
RC254-282 |
| up_date |
2024-07-03T22:17:48.683Z |
| _version_ |
1803597977947734016 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ08430104X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503013056.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2015 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.17650/2220-3478-2013-0-4-7-11</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ08430104X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJe91c09e314a647eaa036ee462346ba84</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">V. Т. Kokhnyuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">FIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTS</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009).</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">colorectal cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cancer-specific survival</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adjuvant chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Тазовая хирургия и онкология</subfield><subfield code="d">“ABV-press” Publishing house”, LLC, 2021</subfield><subfield code="g">(2015), 4, Seite 7-11</subfield><subfield code="w">(DE-627)176063123X</subfield><subfield code="x">26869594</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2015</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:7-11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.17650/2220-3478-2013-0-4-7-11</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/e91c09e314a647eaa036ee462346ba84</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ok.abvpress.ru/jour/article/view/89</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2686-9594</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2015</subfield><subfield code="e">4</subfield><subfield code="h">7-11</subfield></datafield></record></collection>
|
| score |
7.400549 |